Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1980 2
1982 1
1983 1
1984 1
1993 1
1997 1
2000 1
2001 1
2003 1
2004 2
2005 4
2006 1
2007 6
2008 4
2009 5
2010 3
2011 1
2012 5
2015 2
2016 12
2017 23
2018 15
2019 5
2020 19
2021 20
2022 18
2023 17
2024 9
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Fizazi K, et al. Among authors: escande a. Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8. Lancet. 2022. PMID: 35405085 Clinical Trial.
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.
Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, López-Núñez JJ, Otero-Candelera R, Le Gal G, Yeo E, Righini M, Robert-Ebadi H, Huisman MV, Klok FA, Westerweel P, Agnelli G, Becattini C, Bamias A, Syrigos K, Szmit S, Torbicki A, Verhamme P, Maraveyas A, Cohen AT, Ay C, Chapelle C, Meyer G, Couturaud F, Mismetti P, Girard P, Bertoletti L, Laporte S; API-CAT Investigators. Mahé I, et al. N Engl J Med. 2025 Apr 10;392(14):1363-1373. doi: 10.1056/NEJMoa2416112. Epub 2025 Mar 29. N Engl J Med. 2025. PMID: 40162636 Clinical Trial.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Radiotherapy of cervical cancer.
Chargari C, Peignaux K, Escande A, Renard S, Lafond C, Petit A, Lam Cham Kee D, Durdux C, Haie-Méder C. Chargari C, et al. Among authors: escande a. Cancer Radiother. 2022 Feb-Apr;26(1-2):298-308. doi: 10.1016/j.canrad.2021.11.009. Epub 2021 Dec 23. Cancer Radiother. 2022. PMID: 34955418
Reirradiation: A complex situation.
Chargari C, Escande A, Dupuis P, Thariat J. Chargari C, et al. Among authors: escande a. Cancer Radiother. 2022 Oct;26(6-7):911-915. doi: 10.1016/j.canrad.2022.06.016. Epub 2022 Aug 17. Cancer Radiother. 2022. PMID: 35987812 Review.
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.
Ka K, Cordoba A, Cagetti LV, Schiappa R, Kissel M, Escande A, Casabianca LG, Buchalet C, Gouy S, Morice P, Narducci F, Martinez C, Jauffret C, Lambaudie E, Delpech Y, Laas E, Gaillard T, Hannoun-Levi JM, Espenel S, Chargari C. Ka K, et al. Among authors: escande a. Gynecol Oncol. 2024 Sep;188:90-96. doi: 10.1016/j.ygyno.2024.06.010. Epub 2024 Jun 27. Gynecol Oncol. 2024. PMID: 38941964
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment.
Barthélémy P, Thibault C, Fléchon A, Gross-Goupil M, Voog E, Eymard JC, Abraham C, Chasseray M, Lorgis V, Hilgers W, Gobert A, Le Moulec S, Simon C, Nicolas E, Escande A, Pouessel D, Mouillet G, Josse C, Solbes MN, Lambert P, Loriot Y. Barthélémy P, et al. Among authors: escande a. Eur Urol Oncol. 2025 Apr;8(2):407-416. doi: 10.1016/j.euo.2024.09.014. Epub 2024 Oct 24. Eur Urol Oncol. 2025. PMID: 39448350 Free article.
Anaplastic Thyroid Carcinoma: An Update.
Jannin A, Escande A, Al Ghuzlan A, Blanchard P, Hartl D, Chevalier B, Deschamps F, Lamartina L, Lacroix L, Dupuy C, Baudin E, Do Cao C, Hadoux J. Jannin A, et al. Among authors: escande a. Cancers (Basel). 2022 Feb 19;14(4):1061. doi: 10.3390/cancers14041061. Cancers (Basel). 2022. PMID: 35205809 Free PMC article. Review.
168 results